Andrew Abrams

Andrew Abrams is a Partner at New Science Ventures, a venture capital firm focused on building companies that address large unmet needs in the Life Sciences and Information Technology sectors.

Prior to joining New Science Ventures, Andrew was an Associate in J.P. Morgan’s healthcare investment banking practice where he focused on mergers and acquisitions and debt and equity transactions in Europe and the U.S. He advised a wide array of clients spanning the biotechnology, pharmaceutical, medical device, diagnostic and healthcare service sub-sectors. He has also served as an analytical laboratory manager at Monsanto and as business development lead at an early-stage life science tools business, miniPCR bio.

Andrew received his B.A., M.A. and M.Sci. degrees in Natural Sciences and Biochemistry from the University of Cambridge where he was awarded the Richard Perham Scholarship for the most distinguished performance. He also participated in Cambridge’s year-long exchange program with the Massachusetts Institute of Technology. In addition, he holds an M.B.A. from Harvard Business School.